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Bladder cancer continues to result in substantial morbidity and mortality for aﬀected individuals. Advances in the management
of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of ﬁrst-line
treatment. Studies investigating alternative regimes have oﬀered no survival advantage. Targeted therapies may oﬀer beneﬁt either
as single agent or in combinationwith chemotherapy. Symptoms due to metastatic bladder cancer impact patients’ quality of life,
and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of
specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential
treatment modalities, and the evidence to support the management strategies.
1.Introduction
There were over 10,000 new cases of bladder cancer in the
UK in 2008 making it the 7th commonest cancer overall.
A quarter of these are muscle-invasive bladder cancers
(MIBC) [1–5]. Approximately 5% of patients present with
metastatic bladder cancer at diagnosis [5]. In the UK,
the most common histological type of bladder cancer is
transitional cell carcinoma (TCC), however, there are other
types, including squamous cell carcinoma, adenocarcinoma,
and less commonly small cell and small cell and sarcoma.
Factors such as geography and underlying aetiology inﬂu-
ence prevalence across the world [6]. This review will discuss
the current management of patients with metastatic bladder
cancer, in the main of the TCC type, and the evidence to
support this management.
2.Chemotherapy
2.1.First-Line Chemotherapy. Combinationchemotherapy is
the treatment of choice for metastatic bladder can-
cer. Methotrexate, vinblastine, doxorubicin, and cisplatin
(MVAC) was for many years the preferred regime; however,
patients experienced high toxicity levels. Newer chemother-
apy regimes have attempted to oﬀer comparable or better
eﬃcacy in terms of overall survival, response rates, and time
to disease progression whilst decreasing toxicity (Table 1).
In an attempt tooﬀerthe beneﬁtsofMVAC whilst reduc-
ing toxicity, especially neutropenic sepsis, Sternberg et al.
[7] undertook a multicentre study of 263 patients with
metastatic or advanced urothelial tumours who had not
previously received systemic chemotherapy and randomised
them to receive traditional MVAC or high-dose-intensity
MVAC plus granulocyte colony-stimulating factor (HD-
MVAC + GCSF). HD-MVAC + GCSF when compared with
MVAC oﬀered statistically lower levels of grade 3 and 4
neutropenia (20% versus 62%, P<. 001). Although median
survival was unaﬀected, there was a statistically signiﬁcant
improvement in complete response (25% versus 11%, P =
.006) and overall response rate (70% versus 58%, P = .016).
Gemcitabine and cisplatin (GC) been compared with
MVAC in a phase-III randomised controlled trial, which
showed that GC had signiﬁcantly less toxicity with signif-
icantly lower rates of neutropenic sepsis and grade 3 or 4
mucositis and a reduction in drug-related mortality, though
the latter was not statistically signiﬁcant [8]. Response rates2 ISRN Urology
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for GC versus MVAC were 49.4% and 45.7%, respectively,
median survival of 13.8 and 14.8 months, and the time to
progressive disease was identical in both groups at 7.4
months. Furthermore, there were statistically signiﬁcant
higher number of patients with a greater than 5% increase in
weight in the GC group and a reduction in fatigue, although
this was not signiﬁcant. Other quality-of-life markers were
maintained and were similar in both arms.
Triplet combinations with GC have also been studied,
including a single-centre study of the triplet combination
of GC plus paclitaxel [9]. Median survival and median
progression-free survival were 18.5 months and 7 months,
respectively, with a reported response rate of 64.7%. Neu-
tropenia was experienced in 41.2% of participants and
neutropenic sepsis in 32.4%.
Platinum-containing chemotherapy is the gold standard
for patients with metastatic bladder cancer, however, some
patients have inadequate renal function or do not tolerate
cisplatin, for example due to neuropathy. In these patients,
carboplatin has been suggested as an alternative. Bellmunt
et al. [10], Dogliotti et al. [11], and Dreicer et al. [12]
compared cisplatin with carboplatin-containing regimes.
Bellmunt et al. [10] randomised 47 patients to MVAC or
methotrexate, carboplatin, and vinblastine (M-CAVI). There
was a statistically higher median survival in the MVAC
group (16 months versus 9 months, P = .03); however,
response rates were similar. Gemcitabine plus carboplatin
wascomparedwithGCinastudyof110chemonaivepatients
by Dogliotti et al. [11]. No statistically signiﬁcant diﬀerences
were demonstrated in terms of response rate (40% versus
49.1%), complete response (1.8% versus 14.5%), median
time to progression (7.7 months versus 8.3 months), median
survival(9.8monthsversus12.8months),ortoxicity.Dreicer
et al. [12] undertook a phase-III study comparing MVAC
versus paclitaxel plus carboplatin, following observation of
previousgoodresponse.Inthistrial,therewasnostatistically
signiﬁcant improvement in overall survival and response
rates or diﬀerence in quality of life, but there were higher
rates of neutropenia in those receiving MVAC.
A further study by Carles et al. [13] undertook a mul-
ticentre phase-II study using oxaliplatin and gemcitabine.
Chemo-na¨ ıve as well as patients who had received previous
chemotherapy were permitted to enter the study. Complete
response was 6.5% with an overall response rate of 48%. At
the end of study, most of the patients (90%) had progressive
disease with a median time to disease progression of 5
months and a median overall survival of 6.5 months. Grade
3 or 4 neutropenia was reported in 22% of cases.
2.2. Second-Line Chemotherapy. Potential second-line op-
tions in metastatic bladder cancer include single-agent vin-
ﬂunine, taxanes and combination regimes (Table 2). Studies
oftenselectpatientswithperformance status0and1fortheir
inclusion criteria, which may not reﬂect the generally poor-
performance status represented by patients with metastatic
bladder cancer.
A phase-III multi-centre study randomised 370 patients
who had previously progressed through platinum-based
chemotherapy, to receive vinﬂunine and best supportive care
versus best supportive care alone [14]. Overall survival and
progression-free survival were marginally, albeit signiﬁcantly
longer in those receiving vinﬂunine, 6.9 months versus 4.3
months (P = .0 4 ) ,a n d3m o n t h sv e r s u s1 . 5m o n t h s ,
respectively. Vinﬂunine did not impair quality of life.
A phase-II study recruited 45 patients who were treated
with weekly paclitaxel [15]. Overall response was 9%, com-
plete response 2%, median time to progression 3 months,
and median survival 7 months. Febrile neutropenia rates
were 4%. Two weekly versus 3 weekly gemcitabine plus
paclitaxel was investigated by Fechner et al. [16]. Median
time to progression and median survival were not statisti-
cally diﬀerent, however, there was a statistically signiﬁcant
increase in complete response rate in the 3-weekly regime,
though this was a small study.
Pemetrexed withvitamin B12,folicacid,and dexametha-
sone prophylaxis was investigated in a phase-II study to treat
47 patients with progressive disease following adjuvant or
neoadjuvant chemotherapy [17]. Complete response, partial
response, andoverallresponse were6.4%,21.3%,and27.7%,
respectively. Median duration of response was 5 months and
median overall survival 9.6 months. Neutropenic rates were
4.3%.
3.Targeted Therapies
3.1. Histone Deacetylase Inhibitors (HDACi). An imbalance
in the equilibrium of histone acetylation has been asso-
ciated with carcinogenesis and cancer progression. HDAC
inhibitors (HDACis) lead to an accumulation of acetylated
histone proteins in both tumour cells and in normal tissues.
They activate diﬀerentiation, arrest the cell cycle in G1
and/or G2, and induce apoptosis in transformed or cancer
cells. In vitro and in vivo, HDACi demonstrate antitumour
activity, by leading to an accumulation of acetylated histones
and cell cycle arrest and/or apoptosis of some transformed
cells.
HDACi are currently being investigated in ongoing
research studies both in the locally advanced and metastatic
setting [23]. Early phase trials have also investigated using
HDACi concurrently with radiotherapy and chemoradio-
therapy [24–27].
3.2. Epidermal Growth-Factor-Receptor-Targeted Therapy.
Overexpression of epidermal growth factor receptors includ-
ing human epidermal growth factor receptor (EGFR/HER)
has been demonstrated in bladder cancerand may oﬀerboth
prognosticindicatorsaswellasapotentialtargetedtreatment
for metastatic bladder cancer with recommendations sug-
gesting to be used as a supplement to conventional chemo-
therapy.
3.2.1. Trastuzumab. Trials are currently ongoing; however, a
small study by Peyromaure et al. [28] included 6 patients
withmetastaticurothelialcancerandoverexpressionofHER-
2. The participants received trastuzumab and paclitaxel;
carboplatin, trastuzumab, and paclitaxel, or trastuzumab
alone. After 3 cycles, all patients demonstrated a partial
response between 30 and 70%. After 6 cycles, 5 patients4 ISRN Urology
T
a
b
l
e
2
:
S
u
m
m
a
r
y
o
f
l
i
t
e
r
a
t
u
r
e
r
e
l
a
t
e
d
t
o
s
e
c
o
n
d
-
l
i
n
e
c
h
e
m
o
t
h
e
r
a
p
y
a
n
d
t
a
r
g
e
t
e
d
t
h
e
r
a
p
i
e
s
f
o
r
m
e
t
a
s
t
a
t
i
c
b
l
a
d
d
e
r
c
a
n
c
e
r
.
C
h
e
m
o
t
h
e
r
a
p
y
T
a
r
g
e
t
e
d
T
h
e
r
a
p
i
e
s
B
e
l
l
m
u
n
t
e
t
a
l
.
[
1
4
]
B
e
l
l
m
u
n
t
e
t
a
l
.
[
1
4
]
J
o
l
y
e
t
a
l
.
[
1
5
]
F
e
c
h
n
e
r
e
t
a
l
.
2
0
0
6
[
1
6
]
F
e
c
h
n
e
r
e
t
a
l
.
2
0
0
6
[
1
6
]
S
w
e
e
n
e
y
e
t
a
l
.
[
1
7
]
H
u
s
s
a
i
n
e
t
a
l
.
[
1
8
]
W
u
l
ﬁ
n
g
e
t
a
l
.
[
1
9
]
H
a
h
n
e
t
a
l
.
[
2
0
]
R
o
s
e
n
b
e
r
g
e
t
a
l
.
[
2
1
]
G
o
m
e
z
-
A
b
u
i
n
e
t
a
l
.
[
2
2
]
C
h
e
m
o
t
h
e
r
a
p
y
r
e
g
i
m
e
V
i
n
ﬂ
u
n
i
n
e
+
B
e
s
t
s
u
p
p
o
r
t
i
v
e
c
a
r
e
B
e
s
t
s
u
p
p
o
r
t
i
v
e
c
a
r
e
a
l
o
n
e
P
a
c
l
i
t
a
x
e
l
G
e
m
-
P
a
c
3
w
e
e
k
l
y
r
e
g
i
m
e
G
e
m
-
P
a
c
2
w
e
e
k
l
y
r
e
g
i
m
e
P
e
m
e
t
r
e
x
e
d
T
r
a
s
t
u
z
u
m
a
b
p
l
u
s
P
a
c
,
C
a
r
b
o
,
a
n
d
G
e
m
L
a
p
a
t
i
n
i
b
G
C
+
B
e
v
a
c
i
z
u
m
a
b
B
o
r
t
e
z
o
m
i
b
B
o
r
t
e
z
o
m
i
b
R
e
s
p
o
n
s
e
R
a
t
e
(
%
)
8
.
6
0
9
5
0
3
8
2
7
.
7
7
0
3
6
7
0
0
C
o
m
p
l
e
t
e
R
e
s
p
o
n
s
e
r
a
t
e
(
%
)
0
0
2
5
0
7
6
.
4
1
1
.
4
0
1
7
0
0
M
e
d
i
a
n
t
i
m
e
t
o
p
r
o
g
r
e
s
s
i
v
e
d
i
s
e
a
s
e
(
m
o
n
t
h
s
)
3
1
1
6
9
.
3
2
1
.
4
1
.
9
M
e
d
i
a
n
s
u
r
v
i
v
a
l
(
m
o
n
t
h
s
)
6
.
9
4
.
3
7
1
3
9
9
.
6
1
4
4
.
1
1
9
.
1
5
.
7
3
.
5
T
o
x
i
c
i
t
y
G
r
a
d
e
3
o
r
4
N
e
u
t
r
o
p
e
n
i
a
(
%
)
5
0
2
.
7
3
6
2
3
4
.
3
8
6
.
4
3
5
0
0
N
e
u
t
r
o
p
e
n
i
c
s
e
p
s
i
s
o
r
f
e
b
r
i
l
e
n
e
u
t
r
o
p
e
n
i
a
(
%
)
6
0
4
4
0
.
9
2
0
0
D
r
u
g
-
r
e
l
a
t
e
d
d
e
a
t
h
s
(
%
)
5
1
.
7
7
0
0ISRN Urology 5
had progression of at least 1 site of metastatic disease. In
the ﬁve patients who died, the interval between trastuzumab
initiation and patient death ranged from 8 to 18 months.
One patient who received trastuzumab alone remained alive
at 28 months. Grade 4 neutropenia was documented in 1
patient, and there were no cases of congestive heart failure.
The small number of patients included in the study limit
the conclusions that can be drawn from the results, however,
highlight the need for larger trials to investigate the eﬀective-
ness of trastuzumab therapy alone and in combination with
chemotherapy.
The safety and eﬃcacy of trastuzumab in combination
with carboplatin, gemcitabine, and paclitaxel was investi-
gated as part of a phase-II National Cancer Institute trial
[18].PatientswithoverexpressionofHER-2/neureceptoron
immunohistochemistry, gene ampliﬁcation, and/or elevated
serum HER-2/neu, who had not received chemotherapy for
metastatic disease, were treated with a regime comprising
all the four drugs. In those treated, there was a 70% overall
response with a complete response in 11.4%. Median time to
progression was 9.3 months and median survival 14 months.
Toxicities included: grade 3 neutropenia (16%), grade 4
neutropenia (70%), infection-related deaths (5%), overall
cardiac toxicity (14%), and grade III sensory neuropathy
(14%).
In a further phase-II study, Beuzeboc et al. [29]a i m e d
to demonstrate a progression-free survival beneﬁt for those
treated with trastuzumab. Interim safety results concluded
that there were no statistically signiﬁcant diﬀerences in the
rates of toxicity between those receiving trastuzumab plus
chemotherapy versus chemotherapy alone. Eﬃcacy data is
awaited.
3.2.2. Lapatinib. Lapatinib has an established use in HER-2-
positive breast cancer [30] and is being increasingly trailed
in bladder cancer. In a single-arm phase-II study using
Lapatinib as the second-line treatment, there is a correlation
betweenoverexpression ofeGFR/HER-2and response to this
therapy;however,thestatisticallysigniﬁcant beneﬁtrelatesto
the overexpression of eGFR [19].
3.3. Vascular Endothelial-Growth-Factor-Targeted Therapy. A
studyby Bochneretal.[31]exploredtheassociation between
traditional prognostic indicators and tumour angiogenesis.
Estimated probability of recurrence at 5 years for lowest
microvessel counts compared with highest counts were 19%
and 68%; respectively, and overall 5 year survival was 68%
compared to 34%. Tumour angiogenesis is an independent
prognostic indicator in patients with invasive bladder TCC.
Therapies that block vascular endothelial growth factor and
thusthedevelopmentofmicrovesselsmayoﬀeranalternative
treatmentinpatientswithmetastaticbladdercancer.Current
phase-II studies investigating the use of bevacizumab have
shown encouraging results; however, there are concerns
with regards to toxicity. One such study which combined
bevacizumab with cisplatin and gemcitabine as ﬁrst-line
chemotherapy identiﬁed complete response in 17% of
patients with an overall response rate of 67% [20]. Although
the median time to progression appeared comparable to ear-
lier studies using chemotherapy alone, the median survival
appeared to be higher at 19.1 months. There were three
treatment-related deaths, and 21% of patients developed
venous thromboembolism.
3.4.ProteosomeInhibitors. Inhibitorsofthe26Sproteaosome
complex have been shown to arrest tumour spread and
growth and suppress angiogenesis; therefore, it is suggested
that they may oﬀer potential therapeutic approaches. Borte-
zomib, a proteosome inhibitor, has been investigated in two
phase-II single-arm studies to treat advanced or metastatic
urothelial cancers [21, 22]. Both concluded that single-agent
Bortezomib is ineﬀective and does not oﬀer antitumour
activity in this patient group.
4.Radiotherapy
Radiotherapy has several roles in the management of me-
tastaticbladdercancerincludingpalliation ofpain secondary
to bone-metastases, control of advancing pelvic pathology,
and a reduction in urinary symptoms, for example haema-
turia. A variety of potential regimes have been investigated
for the eﬃcacy and toxicity.
An MRC BA09 study by Duchesne et al. [32]c o m p a r e d
two hypofractionated radiotherapy schedulesforlocal symp-
tom control of muscle-invasive bladder cancer, 35Gy in 10
fractions over two weeks versus 21Gy in 3 fractions over one
week. 500 patients were initially randomised with 3-month
follow-up data available in 272 patients. Overall symptom
improvement, deﬁnedas improvementofat least 1 symptom
by 1 grade without worsening another symptom, was 71% in
those receiving 35-Gy compared with 64% in the 21-Gy arm,
though this was not statistically signiﬁcant. Comparing the
35Gy group with the 21Gy group for patients with speciﬁc
pretreatment symptoms, urinary frequency resolved in 43%
and 42%,respectively, nocturia in51%and 35%,haematuria
in 58% and 61%, and dysuria in 47% and 49%. No
diﬀerence in survival or change in WHO performance status
was demonstrated between the two treatment arms. Two-
thirds of participants reported that quality-of-life symptom
scores were either unchanged or improved three months
after treatment. A smaller study by McLaran et al. [33]
treated 65 elderly patients with muscle-invasive bladder
cancer. Treatment involved 30Gy in 5 fractions on a weekly
basis with an additional 6Gy given as the sixth fraction
for participants who were ﬁt, tolerated previous treatment,
and had a ﬁeld size <1000cm3. Complete palliation of
symptoms was achieved in 51% of participants. Frequency
and dysuria resolved in 24%and haematuria resolved in 92%
and frequency and dysuria resolving in 24%. Twenty-eight
patients experienced transient worsening of their urinary
symptoms with eight requiring hospital admission due to
toxicities. The median symptom-free interval was 7 months
(range 0–40 months).
Other common fractionation regimes in use are 20Gy in
5 fractions over one week or a single 8–10Gy fraction.6 ISRN Urology
Severallarge studies investigating the use of radiotherapy
for painful bone-metastases have been reported, comparing
single with multiple fraction regimes. A study from the
Bone Pain Trial working party [34]c o m p a r e d8 - G ys i n g l e -
fraction radiotherapy with a multifraction regime (20Gy
in 5 fractions or 30Gy in 10 fractions) for the treatment
of skeletal-related pain in 765 patients. There were no dif-
ferences demonstrated in the time to response or to ﬁrst
increase in pain at any time up to 12 months. Despite
retreatment being twice as common in those treated with
a single fraction, the authors concluded that retreatment
reﬂected a greater readiness to retreat after a single fraction,
rather than a greater need. A further study by Steenland
et al. [35] compared 8Gy single-fraction radiotherapy with
24Gy in 6 fractions in 1171 patients with metastatic cancer
to bone.There were no statistical diﬀerencesbetweenthetwo
treatment arms in terms of response, change in pain medica-
tion requirements, quality of life, or side eﬀects. Retreatment
rates were higher in those receiving a single fraction.
Although level of pain was the main reason for retreatment,
the authors concluded, as they did in the previous study
discussed, that after a single fraction ofradiotherapy, doctors
were more willing to retreat. Other studies comparing
single- with multifraction radiotherapy for the treatment of
bone-metastases-related painhaveshown comparableresults
[36, 37]. A Cochrane review drew similar conclusions to
the evidence discussed concluding that single-fraction and
multifraction radiotherapy were equally eﬀective in relieving
pain, however, single-fraction radiotherapy conferred an
increased need for retreatment and higher risk of patholog-
ical fractures [38]. It was also stated that quality-of-life and
economic data is required to identify the optimal treatment
regime.
5.Bisphosphonates
Bisphosphonates,aswithothercancers,haveessentiallythree
roles: the management of hypercalcaemia of malignancy,
reduction in skeletal-related events in patients with bone-
metastases and the management of pain related to bone-
metastases. Itiswidely acceptedthat bisphosphonatesreduce
the risk of skeletal complications in multiple cancers,
especially metastatic disease from solid tumours [39–42]
and myeloma [43], and can assist the management of pain
due to bone-metastases. Although more limited, there is
literature to support this theory in patients with bone-
metastases from bladder cancer. A study by Zaghoul et al.
[42]e v a l u a t e dt h ee ﬀect of zoledronic acid on skeletal-
related events.Patients receiving palliative radiotherapy were
randomisedtoplaceboorzoledronicacidfor6months.They
concluded that the patients receiving zoledronic acid had a
lower incidence of skeletal-related events, a prolonged time
to the ﬁrst skeletal-related event and an increased 1-year
survival.
Therecommendeddosetopreventskeletal-relatedevents
in patients with bone-metastases is 4mg zoledronic acid
(Zometa), with the dose adjusted based on baseline creati-
nine clearance (CrCl) in mL/minute [44].
6.PalliativeCare
All the treatment options discussed are being given with
palliative intent to achieve a degree of disease control and aid
symptom management. Improving Outcomes in Urological
Cancers published by the National Institute of Clinical
Excellence in September 2002 stated that palliative care is an
integral part of the management of patients with urological
cancers and should be available if needed to provide symp-
tom control as well as social, spiritual, and psychological
support [45].
This belief is supported by Brierly and O’Brien [46]w h o
reviewed urology outpatient attendances as well as inpatient
admissions and concludedthatpalliative careservices should
be closely involved in the management of patients with uro-
logical cancers and that urologists should develop the skills
required to oﬀer palliative care to their patients. 75% of
patients with terminal malignancy attending outpatients
had problems that would have beneﬁted from specialist
palliative care; however, the number may be higher as psy-
chosocial aspects were not addressed during the assessments
[46].
7.Conclusions
First-line chemotherapy in the metastatic setting is GC or
HD-MVAC + GCSF. The regimes oﬀer comparable eﬀec-
tiveness with reduced toxicity levels compared with the
traditional MVAC regime. Carboplatin-based chemotherapy
regimes oﬀer an alternative to cisplatin-based regimes where
cisplatin is contraindicated. Literature reﬂecting second-line
chemotherapy is limited and needs further investigations.
The novel targeted therapies discussed may oﬀer additional
therapeutic options either in combination with chemother-
apy or as single agents. Further studies would also beneﬁt
from a greater emphasis on quality-of-life measures includ-
ing pain control, which in the palliative setting, is as impor-
tant as the potential response to treatment or survival
advantage.
8.Key Points
(i) First-line chemotherapy in the metastatic setting is
gemcitabine plus cisplatin or high dose intensity
methotrexate, vinblastine, doxorubicin, and cisplatin
(MVAC) plus granulocyte-colony-stimulating factor
(GCSF).
(ii) Novel targeted therapies oﬀer potential additional
therapeutic options; however, additional research is
required.
(iii) Radiotherapy either single- or multifraction regimes
oﬀer symptomatic beneﬁts for bone pain and local-
ised pelvic symptoms.
(iv) Patients with metastatic urothelial cancer demon-
strate substantial morbidity that would beneﬁt from
close involvement with palliative care services.ISRN Urology 7
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